Evaluation and comparison of efficacy and safety of tirzepatide, liraglutide and SGLT2i in patients with type 2 diabetes mellitus: a network meta-analysis.

Teng Y, Fan X, Yu R, Yang X

BMC endocrine disorders24 Dec 2024Cited by 5 (Europe PMC)

PMID39719583PMCIDPMC11668020DOI10.1186/s12902-024-01805-zPepBankPUB-39719583

Read at source PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC-ND. Results still quote short attributed sentences.

Results from this study10

8 results from studies that gave the peptide. 8 results from people.

01HumanSystematic reviewEfficacy outcome
In adults with type 2 diabetes, tirzepatide 15 mg reduced HbA1c more than placebo, the largest reduction of the treatments compared (mean difference -2.24%).
In plain wordsIn adults with type 2 diabetes, tirzepatide 15 mg lowered HbA1c more than placebo, and more than the other treatments compared.
Peptide
Tirzepatide
Outcome
DecreaseHbA1c change, tirzepatide 15 mg
Study
n: not reported in source
Comparator
Placebo
Outcome group
Glycemic control · Metabolic and weight
Studied dose
15 mgAs given in this study (human).
Measurements
HbA1c mean difference
−2.24%
tirzepatide 15 mg vs placebo
Source sentences
Summary
tirzepatide 15 mg reduced HbA1c the most (MD [95% CI], -2.24% [-2.52, -1.96]%)
1 context sentence(design, population, supporting numbers)
Summary · context
Twenty-eight RCTs were included, involving 8499 participants.
Report a problemFND-3971958301
02HumanSystematic reviewEfficacy outcome
In adults with type 2 diabetes, tirzepatide 10 mg reduced HbA1c versus placebo (mean difference -1.99%).
In plain wordsIn adults with type 2 diabetes, tirzepatide 10 mg lowered HbA1c more than placebo.
Peptide
Tirzepatide
Outcome
DecreaseHbA1c change, tirzepatide 10 mg
Study
n: not reported in source
Comparator
Placebo
Outcome group
Glycemic control · Metabolic and weight
Studied dose
10 mgAs given in this study (human).
Measurements
HbA1c mean difference
−1.99%
tirzepatide 10 mg vs placebo
Source sentences
Summary
tirzepatide 10 mg (MD [95% CI], -1.99% [-2.29, -1.69]%)
1 context sentence(design, population, supporting numbers)
Summary · context
Twenty-eight RCTs were included, involving 8499 participants.
Report a problemFND-3971958302
03HumanSystematic reviewEfficacy outcome
In adults with type 2 diabetes, tirzepatide 5 mg reduced HbA1c versus placebo (mean difference -1.82%).
In plain wordsIn adults with type 2 diabetes, tirzepatide 5 mg lowered HbA1c more than placebo.
Peptide
Tirzepatide
Outcome
DecreaseHbA1c change, tirzepatide 5 mg
Study
n: not reported in source
Comparator
Placebo
Outcome group
Glycemic control · Metabolic and weight
Studied dose
5 mgAs given in this study (human).
Measurements
HbA1c mean difference
−1.82%
tirzepatide 5 mg vs placebo
Source sentences
Summary
tirzepatide 5 mg (MD [95% CI], -1.82% [-2.11, -1.53]%)
1 context sentence(design, population, supporting numbers)
Summary · context
Twenty-eight RCTs were included, involving 8499 participants.
Report a problemFND-3971958303
04HumanSystematic reviewEfficacy outcome
In adults with type 2 diabetes, liraglutide 1.2 mg reduced HbA1c versus placebo (mean difference -1.23%).
In plain wordsIn adults with type 2 diabetes, liraglutide 1.2 mg lowered HbA1c more than placebo.
Peptide
Liraglutide
Outcome
DecreaseHbA1c change, liraglutide 1.2 mg
Study
n: not reported in source
Comparator
Placebo
Outcome group
Glycemic control · Metabolic and weight
Studied dose
1.2 mgAs given in this study (human).
Measurements
HbA1c mean difference
−1.23%
liraglutide 1.2 mg vs placebo
Source sentences
Summary
liraglutide 1.2 mg (MD [95% CI], -1.23% [-1.41, -1.05]%)
1 context sentence(design, population, supporting numbers)
Summary · context
Twenty-eight RCTs were included, involving 8499 participants.
Report a problemFND-3971958304
05HumanSystematic reviewEfficacy outcome
In adults with type 2 diabetes, tirzepatide 15 mg reduced body weight versus placebo (mean difference -8.74 kg).
In plain wordsIn adults with type 2 diabetes, tirzepatide 15 mg led to more weight loss than placebo.
Peptide
Tirzepatide
Outcome
DecreaseWeight change, tirzepatide 15 mg
Study
n: not reported in source
Comparator
Placebo
Outcome group
Body weight · Metabolic and weight
Studied dose
15 mgAs given in this study (human).
Measurements
Weight mean difference
−8.74 kg
tirzepatide 15 mg vs placebo
Source sentences
Summary
tirzepatide 15 mg (MD [95% CI], -8.74 kg [-9.83, -7.66] kg)
1 context sentence(design, population, supporting numbers)
Summary · context
Twenty-eight RCTs were included, involving 8499 participants.
Report a problemFND-3971958305
06HumanSystematic reviewEfficacy outcome
In adults with type 2 diabetes, tirzepatide 10 mg reduced body weight versus placebo (mean difference -7.13 kg).
In plain wordsIn adults with type 2 diabetes, tirzepatide 10 mg led to more weight loss than placebo.
Peptide
Tirzepatide
Outcome
DecreaseWeight change, tirzepatide 10 mg
Study
n: not reported in source
Comparator
Placebo
Outcome group
Body weight · Metabolic and weight
Studied dose
10 mgAs given in this study (human).
Measurements
Weight mean difference
−7.13 kg
tirzepatide 10 mg vs placebo
Source sentences
Summary
tirzepatide 10 mg (MD [95% CI], -7.13 kg [-8.40, -5.88] kg)
1 context sentence(design, population, supporting numbers)
Summary · context
Twenty-eight RCTs were included, involving 8499 participants.
Report a problemFND-3971958306
07HumanSystematic reviewEfficacy outcome
In adults with type 2 diabetes, tirzepatide 5 mg reduced body weight versus placebo (mean difference -5.38 kg).
In plain wordsIn adults with type 2 diabetes, tirzepatide 5 mg led to more weight loss than placebo.
Peptide
Tirzepatide
Outcome
DecreaseWeight change, tirzepatide 5 mg
Study
n: not reported in source
Comparator
Placebo
Outcome group
Body weight · Metabolic and weight
Studied dose
5 mgAs given in this study (human).
Measurements
Weight mean difference
−5.38 kg
tirzepatide 5 mg vs placebo
Source sentences
Summary
tirzepatide 5 mg (MD [95% CI], -5.38 kg [-6.65, -4.11] kg)
1 context sentence(design, population, supporting numbers)
Summary · context
Twenty-eight RCTs were included, involving 8499 participants.
Report a problemFND-3971958307
08HumanSystematic reviewSafety outcome
In adults with type 2 diabetes, liraglutide 1.8 mg was the treatment most likely to cause adverse events (OR 2.57).
In plain wordsIn adults with type 2 diabetes, liraglutide 1.8 mg was the treatment most likely to cause side effects of those compared.
Peptide
Liraglutide
Outcome
IncreaseAdverse events, liraglutide 1.8 mg
Study
n: not reported in source
Outcome group
Adverse events · Whole body
Studied dose
1.8 mgAs given in this study (human).
Measurements
Odds ratio
2.57
adverse events, liraglutide 1.8 mg
Source sentences
Summary
Liraglutide 1.8 mg was most likely to cause adverse events (AE) (OR [95% CI], 2.57 [1.78, 3.70])
1 context sentence(design, population, supporting numbers)
Summary · context
Twenty-eight RCTs were included, involving 8499 participants.
Report a problemFND-3971958308

Studies that did not test the peptide alone2

In this study, the peptide was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking the peptide.

09HumanNot a test of Liraglutide aloneSystematic reviewSafety outcome
In adults with type 2 diabetes, there was no significant difference in serious adverse events between the interventions compared, including liraglutide, tirzepatide, SGLT2 inhibitors and placebo.
In plain wordsIn adults with type 2 diabetes, serious side effects did not differ significantly between the compared treatments and placebo.
Peptide
Liraglutide
Outcome
No significant changeSerious adverse events across interventions
Study
n: not reported in source
Comparator
Placebo and other interventions
Outcome group
Adverse events · Whole body
Source sentences
Summary
but there was no significant difference in serious adverse events (SAEs) between the interventions (including placebo).
1 context sentence(design, population, supporting numbers)
Summary · context
Twenty-eight RCTs were included, involving 8499 participants.
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Report a problemFND-3971958309
10HumanNot a test of Tirzepatide aloneSystematic reviewSafety outcome
In adults with type 2 diabetes, there was no significant difference in serious adverse events between the interventions compared, including liraglutide, tirzepatide, SGLT2 inhibitors and placebo.
In plain wordsIn adults with type 2 diabetes, serious side effects did not differ significantly between the compared treatments and placebo.
Peptide
Tirzepatide
Outcome
No significant changeSerious adverse events across interventions
Study
n: not reported in source
Comparator
Placebo and other interventions
Outcome group
Adverse events · Whole body
Source sentences
Summary
but there was no significant difference in serious adverse events (SAEs) between the interventions (including placebo).
1 context sentence(design, population, supporting numbers)
Summary · context
Twenty-eight RCTs were included, involving 8499 participants.
In this study, Tirzepatide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Tirzepatide.
Report a problemFND-3971958310

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 3Current
12 Oct 2026, 11:11 UTC
Study results updated
Version 2
9 Oct 2026, 03:07 UTC
Study data updated · source update from Europe PMC
Version 1
9 Oct 2026, 03:04 UTC
First added · source update from Europe PMC

PepBank is a research reference. Talk to a doctor before you use any peptide.

Evaluation and comparison of efficacy and safety of tirzepatide, liraglutide and SGLT2i in patients with type 2 diabetes mellitus: a network meta-analysis.

Summary

Results from this study10

Studies that did not test the peptide alone2

Version history

Subjects

Publication types

MeSH terms

Keywords